Connect Biopharma Holdings (CNTB) Company Report

Connect Biopharma's rademikibart has demonstrated efficacy and safety across multiple indications, with clinical results showing potential for faster onset of action, greater clinical response (FEV1), and reduction of eosinophils compared to dupilumab.
Phase 2 studies for rademikibart in acute COPD and asthma exacerbations commenced in 2Q2025, with topline data anticipated in mid-2026. The U.S. FDA has agreed that rademikibart is ready for Phase 3 development in chronic asthma and Atopic Dermatitis (AD), although these studies are currently paused until the acute studies are completed.
Simcere, Connect's partner in Greater China, filed an NDA in China for AD in July 2025.
As of September 30, 2025, Connect Biopharma reported cash, cash equivalents, and short-term investments of $54.8 million, which are projected to fund planned operations into 2027.

Jan 12, 2026, 12:00 PM

Presentation

Connect Biopharma Provides Update on Retimicavir Development for Acute Asthma and COPD

CNTB

New Projects/Investments

Guidance Update

Revenue Acceleration/Inflection

Connect Biopharma is developing retimicavir, a next-generation IL-4 receptor alpha monoclonal antibody, for acute asthma and COPD exacerbations, differentiated by its rapid onset of effect within hours.
The company is conducting two Phase 2 studies (160 patients each) for these indications, with top-line data anticipated in the first half of next year.
Retimicavir targets a market with no current biologic competition for acute treatment, with the potential to serve as a gateway to a multi-billion dollar chronic use market.
Connect Biopharma has cash and runway into 2027, providing financial support through the upcoming data readouts and potential Phase 3 initiation.
Following successful Phase 2 data, the company plans to engage with the FDA to define a Phase 3 pathway, with studies potentially starting as early as late next year.

Dec 2, 2025, 3:50 PM

Transcript

Connect Biopharma Provides Update on Retimicavir Development and Acute Exacerbation Trials

CNTB

New Projects/Investments

Guidance Update

Connect Biopharma is developing retimicavir (CBP-201), a next-generation IL-4 receptor alpha monoclonal antibody, which demonstrates a rapid onset of effect within hours for airway function, efficacy with q4 week dosing, and a distinct eosinophil safety profile compared to Dupixent.
The company is primarily focusing on the acute treatment of asthma and COPD exacerbations, an area with no approved biologic treatments, representing a potential market of four million patients seeking medical care for acute episodes.
Two global Phase 2 studies for acute asthma and COPD exacerbations, each targeting 160 patients, are currently underway, with data anticipated in the first half of next year.
Connect Biopharma has cash and runway into 2027, and successful Phase 2 results could lead to Phase 3 studies for the acute setting starting as early as late next year.
A licensed Chinese partner has filed an NDA for atopic dermatitis, with approval hoped for mid-next year, and is conducting a Phase 3 asthma study, which could support US chronic indications.

Dec 2, 2025, 3:50 PM

Transcript

Connect Biopharma Updates on Retimicavir Development for Acute Asthma and COPD Exacerbations

CNTB

New Projects/Investments

Guidance Update

Connect Biopharma is developing retimicavir (CBP-201), a next-generation IL-4 receptor alpha monoclonal antibody, primarily for acute asthma and COPD exacerbations.
Retimicavir is differentiated by its very rapid onset of effect (within hours) on airway function and a safety profile that decreases eosinophils, unlike Dupixent.
The company is conducting two Phase 2 studies for acute asthma and COPD exacerbations, targeting 160 patients each, with data expected in the first half of 2026.
Connect Biopharma has cash and runway into 2027.

Dec 2, 2025, 3:50 PM

Transcript

Connect Biopharma Reports Q3 2025 Financial Results and Business Updates

CNTB

Earnings

Guidance Update

New Projects/Investments

Connect Biopharma reported cash, cash equivalents and short-term investments of $54.8 million as of September 30, 2025, which is expected to fund operations into 2027.
The New Drug Application for rademikibart for atopic dermatitis, submitted by Connect Biopharma's exclusive licensee Simcere, was accepted by China's NMPA in July 2025.
Recruitment is ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD, with topline data from both studies anticipated in the first half of 2026.
For the three months ended September 30, 2025, the company reported a net loss of $17.2 million, or $0.31 per share, and license and collaboration revenues of $16,000.

Nov 12, 2025, 2:02 PM

8-K

Connect Biopharma Updates on U.S. Centric Strategy, Rademikibart Development, and Financial Position

CNTB

New Projects/Investments

Guidance Update

Revenue Acceleration/Inflection

Connect Biopharma is transitioning to a U.S.-centric company, moving its headquarters to San Diego and converting from ADRs to ordinary shares on NASDAQ.
The company is focusing its lead program, rademikibart, on treating acute exacerbations in asthma and COPD, with Phase 2 data expected in the first half of next year.
Rademikibart has demonstrated fast onset of effect (within hours) and a favorable safety profile compared to Dupilumab, with no current biologic competition for acute exacerbation treatment.
Connect Biopharma holds a strong cash position of $72 million as of Q2, providing runway into 2027, and has $110 million in remaining milestones from its partnership with Simcere Pharmaceutical Group for rademikibart in Greater China.

Nov 3, 2025, 9:15 PM

Transcript

Konnect Biopharma Details Rademikabart Development Strategy and Financial Outlook

CNTB

New Projects/Investments

Guidance Update

Konnect Biopharma (CNTB) is strategically focusing its lead product, Rademikabart, an IL-4 receptor alpha antibody, on the treatment of acute exacerbations of asthma and COPD due to its rapid onset of effect and differentiated safety profile compared to DUPIXENT.
The company is currently conducting two parallel Phase 2 studies for acute exacerbations in asthma and COPD, with top-line data anticipated in H1 2026.
Rademikabart targets a significant unmet need, as there have been no new drugs for acute exacerbations in over 30 years, with an addressable market of approximately 4 million patients annually in the US.
As of Q2 2025, CNTB reported approximately $72 million in cash, which is expected to fund current trials and extend its cash runway into 2027.

Sep 3, 2025, 8:26 PM

Connect Biopharma provides update on rademikibart development and financial position

CNTB

New Projects/Investments

Guidance Update

Connect Biopharma (CNTB) has transitioned to a U.S.-centric organization, focusing on the development of rademikibart, an IL-4 receptor alpha antibody, for respiratory diseases.
The company is targeting the acute exacerbation market in asthma and COPD, addressing an unmet need for approximately 4 million patients annually, with no novel drug approvals in over 30 years.
Two parallel Phase II studies for acute exacerbations in asthma and COPD are currently enrolling, with top-line data anticipated in the first half of 2026.
Connect Biopharma reported approximately $72 million in cash at the end of Q2 2025, which is expected to fund current trials down to $27 million.

Sep 3, 2025, 7:20 PM

Transcript

Connect Biopharma Provides Update on Radimicavart Development and Financials

CNTB

New Projects/Investments

Guidance Update

Connect Biopharma (CNTB) has transitioned to a U.S.-centric organization, moving its headquarters to San Diego and now trading ordinary shares to enhance interest among U.S. investors.
The company's lead product, Radimicavart, an IL-4 receptor alpha antibody, is being developed for acute exacerbations of asthma and COPD, targeting an addressable market of approximately 4 million patients who currently lack novel treatments.
Radimicavart has demonstrated a very rapid onset of effect, with significant airway improvement observed within hours of administration, distinguishing it from current biologics that are not indicated for acute treatment.
Connect Biopharma is conducting two Phase 2 trials for acute exacerbations in asthma and COPD, with top-line data expected in the first half of next year (2026).
The company reported approximately $72 million in cash at the end of Q2, with cash down to $27 million, and anticipates Phase 1 IV study data before year-end (2025) as a near-term catalyst.